FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for preparation of medication for treatment of cancer with expression of TLR3 in patient. For this purpose used is TLR3 agonist in combination with type I interferon in low dose. Impact efficiency is conditioned by synergic effect between TLR3 agonist and interferon.
EFFECT: invention allows to affect tumour due to induction of apoptosis in cancer cell TLR3 expressing.
18 cl, 14 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICAMENT | 2016 |
|
RU2709015C2 |
| IMMUNOSTIMULATING COMBINATION FOR PREVENTION AND TREATMENT OF HEPATITIS C | 2006 |
|
RU2431499C2 |
| MEDICINAL PRODUCT | 2017 |
|
RU2759728C2 |
| IMPROVED VECTOR EXPRESSING TOLL-LIKE RECEPTOR AND AGONIST, AND USE IN CANCER THERAPY | 2014 |
|
RU2682762C2 |
| IMMUNOSTIMULATING G,U-CONTAINING OLYGORIBONUCLEOTIDES | 2003 |
|
RU2302865C2 |
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
| TLR3-BINDING AGENTS | 2010 |
|
RU2562865C2 |
| COMPOSITIONS CAUSING SPECIFIC RESPONSE OF CYTOTOXIC T-LYMPHOCYTES, INCLUDING LYMPH-ABLATIVE COMPOUND AND MOLECULE WHICH CONTAINS ANTIGEN SEQUENCES AND IS TARGETED AT SPECIALISED ANTIGEN-PRESENTING CELLS | 2007 |
|
RU2448729C2 |
| TLR3 LIGANDS WHICH ACTIVATE BOTH EPITHELIAL AND MYELOID CELLS | 2019 |
|
RU2826262C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
